A new galium-68 (Ga-68)-labeled PET/CT radiotracer appears superior over F-18 FDG for detecting bone metastases, particularly in patients with osteoblastic lesions and prostate cancer, a group in China has reported.
The finding is from a prospective trial comparing Ga-68 DOTA-IBA-PET/CT to F-18 FDG-PET/CT in 46 patients and supports the use of the tracer as a theranostics imaging agent, noted corresponding author Yue Chen, MD, of Southwest Medical University in Sichuan, and colleagues.
“Our study supports the rationale for using Ga-68 DOTA-IBA to improve the management of patients with bone metastases, considering the therapeutic efficacy of [lutetium-177] DOTA-IBA,” the group wrote. The study was published April 14 in Scientific Reports.
Theranostics is an innovative nuclear medicine treatment approach that…